OBJECTIVE: We conducted a pilot survey to evaluate breast cancer patients' willingness to participate in a preoperative chemoprevention (ie, window-of-opportunity) study. Design A 27-question written survey was developed and administered to participants. Setting A breast cancer specialty clinic at the University of Wisconsin Hospital and Clinics. Participants 30 adult patients with newly diagnosed operable breast cancer participated after signing informed consent. METHODS: A convenience sample of 30 participants was recruited from July 2005 through January 2006. Participants were administered the survey in clinic. Univariate ordinal logistic regression models were used to identify predictors of willingness to participate in window-of-opportunity trials. RESULTS: Overall, 26.7% of respondents were willing to participate in a research trial between the time of breast cancer diagnosis and surgery. Univariate ordinal logistic regression models identified that women with a prior history of breast cancer (P=0.060), prior research participation (P=0.006), more education (P=0.034), and self-reported breast cancer knowledge (P=0.043) were more willing to participate. On average, women preferred to have surgery 7 days (range 1-14) after their diagnosis, but the actual average wait time between diagnostic biopsy and surgery was 37.5 days (standard deviation = 23.4 days). CONCLUSION: There is ample time before breast surgery to conduct preoperative window-of-opportunity trials. Interventions aimed at expanding patients' breast cancer knowledge may improve accrual to window-of-opportunity studies.
OBJECTIVE: We conducted a pilot survey to evaluate breast cancerpatients' willingness to participate in a preoperative chemoprevention (ie, window-of-opportunity) study. Design A 27-question written survey was developed and administered to participants. Setting A breast cancer specialty clinic at the University of Wisconsin Hospital and Clinics. Participants 30 adult patients with newly diagnosed operable breast cancer participated after signing informed consent. METHODS: A convenience sample of 30 participants was recruited from July 2005 through January 2006. Participants were administered the survey in clinic. Univariate ordinal logistic regression models were used to identify predictors of willingness to participate in window-of-opportunity trials. RESULTS: Overall, 26.7% of respondents were willing to participate in a research trial between the time of breast cancer diagnosis and surgery. Univariate ordinal logistic regression models identified that women with a prior history of breast cancer (P=0.060), prior research participation (P=0.006), more education (P=0.034), and self-reported breast cancer knowledge (P=0.043) were more willing to participate. On average, women preferred to have surgery 7 days (range 1-14) after their diagnosis, but the actual average wait time between diagnostic biopsy and surgery was 37.5 days (standard deviation = 23.4 days). CONCLUSION: There is ample time before breast surgery to conduct preoperative window-of-opportunity trials. Interventions aimed at expanding patients' breast cancer knowledge may improve accrual to window-of-opportunity studies.
Entities:
Keywords:
Breast Cancer; Chemoprevention; Survey; Window-of-Opportunity
Authors: Sirwan Hadad; Takayuki Iwamoto; Lee Jordan; Colin Purdie; Susan Bray; Lee Baker; Gera Jellema; Steve Deharo; D Grahame Hardie; Lajos Pusztai; Stacy Moulder-Thompson; John A Dewar; Alastair M Thompson Journal: Breast Cancer Res Treat Date: 2011-06-08 Impact factor: 4.872
Authors: W C Dooley; B M Ljung; U Veronesi; M Cazzaniga; R M Elledge; J A O'Shaughnessy; H M Kuerer; D T Hung; S A Khan; R F Phillips; P A Ganz; D M Euhus; L J Esserman; B G Haffty; B L King; M C Kelley; M M Anderson; P J Schmit; R R Clark; F C Kass; B O Anderson; S L Troyan; R D Arias; J N Quiring; S M Love; D L Page; E B King Journal: J Natl Cancer Inst Date: 2001-11-07 Impact factor: 13.506
Authors: Edward Messing; Jason R Gee; Daniel R Saltzstein; KyungMann Kim; Anthony diSant'Agnese; Jill Kolesar; Linda Harris; Adrienne Faerber; Thomas Havighurst; Jay M Young; Mitchell Efros; Robert H Getzenberg; Marcia A Wheeler; Joseph Tangrea; Howard Parnes; Margaret House; J Erik Busby; Raymond Hohl; Howard Bailey Journal: Cancer Prev Res (Phila) Date: 2012-01-31
Authors: E Singletary; R Lieberman; N Atkinson; N Sneige; A Sahin; S Tolley; M Colchin; T Bevers; C Stelling; B Fornage; H Fritsche; W Hittelman; G Kelloff; S M Lippman Journal: Cancer Epidemiol Biomarkers Prev Date: 2000-10 Impact factor: 4.254
Authors: S Eva Singletary; Edward N Atkinson; Ashraful Hoque; Nour Sneige; Ayse A Sahin; Herbert A Fritsche; Reuben Lotan; Tao Lu; Walter N Hittelman; Therese B Bevers; Carol B Stelling; Scott M Lippman Journal: Clin Cancer Res Date: 2002-09 Impact factor: 12.531
Authors: Andrea Decensi; Chris Robertson; Giuseppe Viale; Francesca Pigatto; Harriet Johansson; Elton R Kisanga; Paolo Veronesi; Rosalba Torrisi; Massimiliano Cazzaniga; Serena Mora; Maria T Sandri; Giuseppe Pelosi; Alberto Luini; Aron Goldhirsch; Ernst A Lien; Umberto Veronesi Journal: J Natl Cancer Inst Date: 2003-06-04 Impact factor: 13.506
Authors: Bradley C Carthon; Jedd D Wolchok; Jianda Yuan; Ashish Kamat; Derek S Ng Tang; Jingjing Sun; Geoffrey Ku; Patricia Troncoso; Christopher J Logothetis; James P Allison; Padmanee Sharma Journal: Clin Cancer Res Date: 2010-05-11 Impact factor: 12.531
Authors: Lesley-Ann Martin; Giles L S Davies; Marion T Weigel; Nadine Betambeau; Margaret J Hills; Janine Salter; Geraldine Walsh; Roger A'Hern; Mitch Dowsett Journal: Breast Cancer Res Treat Date: 2010-08-10 Impact factor: 4.872
Authors: Adam L Cohen; Leigh Neumayer; Ken Boucher; Rachel E Factor; Gajendra Shrestha; Mark Wade; John G Lamb; Kylee Arbogast; Stephen R Piccolo; Joanna Riegert; Matthias Schabel; Andrea H Bild; Theresa L Werner Journal: JCO Precis Oncol Date: 2017-04-07
Authors: George W Sledge; Jennifer L Caswell-Jin; Divya A Parikh; Lisa Kody; Susie Brain; Diane Heditsian; Vivian Lee; Christina Curtis; Mardi R Karin; Irene L Wapnir; Manali I Patel Journal: Breast Cancer Res Treat Date: 2022-05-11 Impact factor: 4.624
Authors: Angel Arnaout; Susan Robertson; Iryna Kuchuk; Demetrios Simos; Gregory R Pond; Christina L Addison; Mehrzad Namazi; Mark Clemons Journal: Int J Surg Oncol Date: 2015-01-20